 | • レポートコード：MRC2-11QY07606 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は髄膜腫治療薬のグローバル市場について調査・分析したレポートです。種類別（アベマシクリブ、ジマレイン酸アファチニブ、AR-42、アベルマブ、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別髄膜腫治療薬の競争状況、市場シェア ・世界の髄膜腫治療薬市場：種類別市場規模 2015年-2020年（アベマシクリブ、ジマレイン酸アファチニブ、AR-42、アベルマブ、その他） ・世界の髄膜腫治療薬市場：種類別市場規模予測 2021年-2026年（アベマシクリブ、ジマレイン酸アファチニブ、AR-42、アベルマブ、その他） ・世界の髄膜腫治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の髄膜腫治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の髄膜腫治療薬市場分析：米国、カナダ ・ヨーロッパの髄膜腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの髄膜腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の髄膜腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの髄膜腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Arno Therapeutics Inc、AstraZeneca Plc、Boehringer Ingelheim GmbH、Eli Lilly and Co、Genentech Inc、GlaxoSmithKline Plc、Merck & Co Inc、Merck KGaA、Novartis AG、Ono Pharmaceutical Co Ltd、Pharma Mar SA、Progenics Pharmaceuticals Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Meningioma Drug Market
The global Meningioma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Meningioma Drug Scope and Market Size
Meningioma Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Meningioma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Meningioma Drug market is segmented into
Abemaciclib
Afatinib Dimaleate
AR-42
Avelumab
Others
Segment by Application, the Meningioma Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Meningioma Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Meningioma Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Meningioma Drug Market Share Analysis
Meningioma Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Meningioma Drug business, the date to enter into the Meningioma Drug market, Meningioma Drug product introduction, recent developments, etc.
The major vendors covered:
Arno Therapeutics Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Genentech Inc
GlaxoSmithKline Plc
Merck & Co Inc
Merck KGaA
Novartis AG
Ono Pharmaceutical Co Ltd
Pharma Mar SA
Progenics Pharmaceuticals Inc
1 Study Coverage
1.1 Meningioma Drug Product Introduction
1.2 Market Segments
1.3 Key Meningioma Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Meningioma Drug Market Size Growth Rate by Type
1.4.2 Abemaciclib
1.4.3 Afatinib Dimaleate
1.4.4 AR-42
1.4.5 Avelumab
1.4.6 Others
1.5 Market by Application
1.5.1 Global Meningioma Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Meningioma Drug Market Size, Estimates and Forecasts
2.1.1 Global Meningioma Drug Revenue 2015-2026
2.1.2 Global Meningioma Drug Sales 2015-2026
2.2 Global Meningioma Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Meningioma Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Meningioma Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Meningioma Drug Competitor Landscape by Players
3.1 Meningioma Drug Sales by Manufacturers
3.1.1 Meningioma Drug Sales by Manufacturers (2015-2020)
3.1.2 Meningioma Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Meningioma Drug Revenue by Manufacturers
3.2.1 Meningioma Drug Revenue by Manufacturers (2015-2020)
3.2.2 Meningioma Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Meningioma Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Meningioma Drug Revenue in 2019
3.2.5 Global Meningioma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Meningioma Drug Price by Manufacturers
3.4 Meningioma Drug Manufacturing Base Distribution, Product Types
3.4.1 Meningioma Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Meningioma Drug Product Type
3.4.3 Date of International Manufacturers Enter into Meningioma Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Meningioma Drug Market Size by Type (2015-2020)
4.1.1 Global Meningioma Drug Sales by Type (2015-2020)
4.1.2 Global Meningioma Drug Revenue by Type (2015-2020)
4.1.3 Meningioma Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Meningioma Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Meningioma Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Meningioma Drug Revenue Forecast by Type (2021-2026)
4.2.3 Meningioma Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Meningioma Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Meningioma Drug Market Size by Application (2015-2020)
5.1.1 Global Meningioma Drug Sales by Application (2015-2020)
5.1.2 Global Meningioma Drug Revenue by Application (2015-2020)
5.1.3 Meningioma Drug Price by Application (2015-2020)
5.2 Meningioma Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Meningioma Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Meningioma Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Meningioma Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Meningioma Drug by Country
6.1.1 North America Meningioma Drug Sales by Country
6.1.2 North America Meningioma Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Meningioma Drug Market Facts & Figures by Type
6.3 North America Meningioma Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Meningioma Drug by Country
7.1.1 Europe Meningioma Drug Sales by Country
7.1.2 Europe Meningioma Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Meningioma Drug Market Facts & Figures by Type
7.3 Europe Meningioma Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Meningioma Drug by Region
8.1.1 Asia Pacific Meningioma Drug Sales by Region
8.1.2 Asia Pacific Meningioma Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Meningioma Drug Market Facts & Figures by Type
8.3 Asia Pacific Meningioma Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Meningioma Drug by Country
9.1.1 Latin America Meningioma Drug Sales by Country
9.1.2 Latin America Meningioma Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Meningioma Drug Market Facts & Figures by Type
9.3 Central & South America Meningioma Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Meningioma Drug by Country
10.1.1 Middle East and Africa Meningioma Drug Sales by Country
10.1.2 Middle East and Africa Meningioma Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Meningioma Drug Market Facts & Figures by Type
10.3 Middle East and Africa Meningioma Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Arno Therapeutics Inc
11.1.1 Arno Therapeutics Inc Corporation Information
11.1.2 Arno Therapeutics Inc Description and Business Overview
11.1.3 Arno Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Arno Therapeutics Inc Meningioma Drug Products Offered
11.1.5 Arno Therapeutics Inc Related Developments
11.2 AstraZeneca Plc
11.2.1 AstraZeneca Plc Corporation Information
11.2.2 AstraZeneca Plc Description and Business Overview
11.2.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Plc Meningioma Drug Products Offered
11.2.5 AstraZeneca Plc Related Developments
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Corporation Information
11.3.2 Boehringer Ingelheim GmbH Description and Business Overview
11.3.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Boehringer Ingelheim GmbH Meningioma Drug Products Offered
11.3.5 Boehringer Ingelheim GmbH Related Developments
11.4 Eli Lilly and Co
11.4.1 Eli Lilly and Co Corporation Information
11.4.2 Eli Lilly and Co Description and Business Overview
11.4.3 Eli Lilly and Co Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Eli Lilly and Co Meningioma Drug Products Offered
11.4.5 Eli Lilly and Co Related Developments
11.5 Genentech Inc
11.5.1 Genentech Inc Corporation Information
11.5.2 Genentech Inc Description and Business Overview
11.5.3 Genentech Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Genentech Inc Meningioma Drug Products Offered
11.5.5 Genentech Inc Related Developments
11.6 GlaxoSmithKline Plc
11.6.1 GlaxoSmithKline Plc Corporation Information
11.6.2 GlaxoSmithKline Plc Description and Business Overview
11.6.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Plc Meningioma Drug Products Offered
11.6.5 GlaxoSmithKline Plc Related Developments
11.7 Merck & Co Inc
11.7.1 Merck & Co Inc Corporation Information
11.7.2 Merck & Co Inc Description and Business Overview
11.7.3 Merck & Co Inc Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck & Co Inc Meningioma Drug Products Offered
11.7.5 Merck & Co Inc Related Developments
11.8 Merck KGaA
11.8.1 Merck KGaA Corporation Information
11.8.2 Merck KGaA Description and Business Overview
11.8.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Merck KGaA Meningioma Drug Products Offered
11.8.5 Merck KGaA Related Developments
11.9 Novartis AG
11.9.1 Novartis AG Corporation Information
11.9.2 Novartis AG Description and Business Overview
11.9.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Novartis AG Meningioma Drug Products Offered
11.9.5 Novartis AG Related Developments
11.10 Ono Pharmaceutical Co Ltd
11.10.1 Ono Pharmaceutical Co Ltd Corporation Information
11.10.2 Ono Pharmaceutical Co Ltd Description and Business Overview
11.10.3 Ono Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Ono Pharmaceutical Co Ltd Meningioma Drug Products Offered
11.10.5 Ono Pharmaceutical Co Ltd Related Developments
11.1 Arno Therapeutics Inc
11.1.1 Arno Therapeutics Inc Corporation Information
11.1.2 Arno Therapeutics Inc Description and Business Overview
11.1.3 Arno Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Arno Therapeutics Inc Meningioma Drug Products Offered
11.1.5 Arno Therapeutics Inc Related Developments
11.12 Progenics Pharmaceuticals Inc
11.12.1 Progenics Pharmaceuticals Inc Corporation Information
11.12.2 Progenics Pharmaceuticals Inc Description and Business Overview
11.12.3 Progenics Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Progenics Pharmaceuticals Inc Products Offered
11.12.5 Progenics Pharmaceuticals Inc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Meningioma Drug Market Estimates and Projections by Region
12.1.1 Global Meningioma Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Meningioma Drug Revenue Forecast by Regions 2021-2026
12.2 North America Meningioma Drug Market Size Forecast (2021-2026)
12.2.1 North America: Meningioma Drug Sales Forecast (2021-2026)
12.2.2 North America: Meningioma Drug Revenue Forecast (2021-2026)
12.2.3 North America: Meningioma Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Meningioma Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Meningioma Drug Sales Forecast (2021-2026)
12.3.2 Europe: Meningioma Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Meningioma Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Meningioma Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Meningioma Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Meningioma Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Meningioma Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Meningioma Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Meningioma Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Meningioma Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Meningioma Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Meningioma Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Meningioma Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Meningioma Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Meningioma Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Meningioma Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Meningioma Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Meningioma Drug Market Segments
Table 2. Ranking of Global Top Meningioma Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Meningioma Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Abemaciclib
Table 5. Major Manufacturers of Afatinib Dimaleate
Table 6. Major Manufacturers of AR-42
Table 7. Major Manufacturers of Avelumab
Table 8. Major Manufacturers of Others
Table 9. Global Meningioma Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Meningioma Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Meningioma Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Meningioma Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Meningioma Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Meningioma Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Meningioma Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Meningioma Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Meningioma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Meningioma Drug as of 2019)
Table 18. Meningioma Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Meningioma Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Meningioma Drug Price (2015-2020) (USD/Pcs)
Table 21. Meningioma Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Meningioma Drug Product Type
Table 23. Date of International Manufacturers Enter into Meningioma Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Meningioma Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Meningioma Drug Sales Share by Type (2015-2020)
Table 27. Global Meningioma Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Meningioma Drug Revenue Share by Type (2015-2020)
Table 29. Meningioma Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Meningioma Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Meningioma Drug Sales Share by Application (2015-2020)
Table 32. North America Meningioma Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Meningioma Drug Sales Market Share by Country (2015-2020)
Table 34. North America Meningioma Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Meningioma Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Meningioma Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Meningioma Drug Sales Market Share by Type (2015-2020)
Table 38. North America Meningioma Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Meningioma Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Meningioma Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Meningioma Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Meningioma Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Meningioma Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Meningioma Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Meningioma Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Meningioma Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Meningioma Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Meningioma Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Meningioma Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Meningioma Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Meningioma Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Meningioma Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Meningioma Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Meningioma Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Meningioma Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Meningioma Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Meningioma Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Meningioma Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Meningioma Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Meningioma Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Meningioma Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Meningioma Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Meningioma Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Meningioma Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Meningioma Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Meningioma Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Meningioma Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Meningioma Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Meningioma Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Meningioma Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Meningioma Drug Sales Market Share by Application (2015-2020)
Table 72. Arno Therapeutics Inc Corporation Information
Table 73. Arno Therapeutics Inc Description and Major Businesses
Table 74. Arno Therapeutics Inc Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Arno Therapeutics Inc Product
Table 76. Arno Therapeutics Inc Recent Development
Table 77. AstraZeneca Plc Corporation Information
Table 78. AstraZeneca Plc Description and Major Businesses
Table 79. AstraZeneca Plc Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. AstraZeneca Plc Product
Table 81. AstraZeneca Plc Recent Development
Table 82. Boehringer Ingelheim GmbH Corporation Information
Table 83. Boehringer Ingelheim GmbH Description and Major Businesses
Table 84. Boehringer Ingelheim GmbH Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Boehringer Ingelheim GmbH Product
Table 86. Boehringer Ingelheim GmbH Recent Development
Table 87. Eli Lilly and Co Corporation Information
Table 88. Eli Lilly and Co Description and Major Businesses
Table 89. Eli Lilly and Co Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Eli Lilly and Co Product
Table 91. Eli Lilly and Co Recent Development
Table 92. Genentech Inc Corporation Information
Table 93. Genentech Inc Description and Major Businesses
Table 94. Genentech Inc Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Genentech Inc Product
Table 96. Genentech Inc Recent Development
Table 97. GlaxoSmithKline Plc Corporation Information
Table 98. GlaxoSmithKline Plc Description and Major Businesses
Table 99. GlaxoSmithKline Plc Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. GlaxoSmithKline Plc Product
Table 101. GlaxoSmithKline Plc Recent Development
Table 102. Merck & Co Inc Corporation Information
Table 103. Merck & Co Inc Description and Major Businesses
Table 104. Merck & Co Inc Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Merck & Co Inc Product
Table 106. Merck & Co Inc Recent Development
Table 107. Merck KGaA Corporation Information
Table 108. Merck KGaA Description and Major Businesses
Table 109. Merck KGaA Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Merck KGaA Product
Table 111. Merck KGaA Recent Development
Table 112. Novartis AG Corporation Information
Table 113. Novartis AG Description and Major Businesses
Table 114. Novartis AG Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. Novartis AG Product
Table 116. Novartis AG Recent Development
Table 117. Ono Pharmaceutical Co Ltd Corporation Information
Table 118. Ono Pharmaceutical Co Ltd Description and Major Businesses
Table 119. Ono Pharmaceutical Co Ltd Meningioma Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 120. Ono Pharmaceutical Co Ltd Product
Table 121. Ono Pharmaceutical Co Ltd Recent Development
Table 122. Pharma Mar SA Corporation Information
Table 123. Pharma Mar SA Description and Major Businesses
Table 124. Pharma Mar SA Meningioma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 125. Pharma Mar SA Product
Table 126. Pharma Mar SA Recent Development
Table 127. Progenics Pharmaceuticals Inc Corporation Information
Table 128. Progenics Pharmaceuticals Inc Description and Major Businesses
Table 129. Progenics Pharmaceuticals Inc Meningioma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 130. Progenics Pharmaceuticals Inc Product
Table 131. Progenics Pharmaceuticals Inc Recent Development
Table 132. Global Meningioma Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 133. Global Meningioma Drug Sales Market Share Forecast by Regions (2021-2026)
Table 134. Global Meningioma Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 135. Global Meningioma Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 136. North America: Meningioma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 137. North America: Meningioma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Europe: Meningioma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 139. Europe: Meningioma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Asia Pacific: Meningioma Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 141. Asia Pacific: Meningioma Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 142. Latin America: Meningioma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 143. Latin America: Meningioma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Middle East and Africa: Meningioma Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 145. Middle East and Africa: Meningioma Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 147. Key Challenges
Table 148. Market Risks
Table 149. Main Points Interviewed from Key Meningioma Drug Players
Table 150. Meningioma Drug Customers List
Table 151. Meningioma Drug Distributors List
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Meningioma Drug Product Picture
Figure 2. Global Meningioma Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Abemaciclib Product Picture
Figure 4. Afatinib Dimaleate Product Picture
Figure 5. AR-42 Product Picture
Figure 6. Avelumab Product Picture
Figure 7. Others Product Picture
Figure 8. Global Meningioma Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Meningioma Drug Report Years Considered
Figure 13. Global Meningioma Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Meningioma Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Meningioma Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Meningioma Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Meningioma Drug Sales Market Share by Region in 2019
Figure 18. Global Meningioma Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Meningioma Drug Revenue Market Share by Region in 2019
Figure 20. Global Meningioma Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Meningioma Drug Revenue in 2019
Figure 22. Meningioma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Meningioma Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Meningioma Drug Sales Market Share by Type in 2019
Figure 25. Global Meningioma Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Meningioma Drug Revenue Market Share by Type in 2019
Figure 27. Global Meningioma Drug Market Share by Price Range (2015-2020)
Figure 28. Global Meningioma Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Meningioma Drug Sales Market Share by Application in 2019
Figure 30. Global Meningioma Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Meningioma Drug Revenue Market Share by Application in 2019
Figure 32. North America Meningioma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Meningioma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Meningioma Drug Sales Market Share by Country in 2019
Figure 35. North America Meningioma Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Meningioma Drug Market Share by Type in 2019
Figure 41. North America Meningioma Drug Market Share by Application in 2019
Figure 42. Europe Meningioma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Meningioma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Meningioma Drug Sales Market Share by Country in 2019
Figure 45. Europe Meningioma Drug Revenue Market Share by Country in 2019
Figure 46. Germany Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Meningioma Drug Market Share by Type in 2019
Figure 57. Europe Meningioma Drug Market Share by Application in 2019
Figure 58. Asia Pacific Meningioma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Meningioma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Meningioma Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Meningioma Drug Revenue Market Share by Region in 2019
Figure 62. China Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Meningioma Drug Market Share by Type in 2019
Figure 85. Asia Pacific Meningioma Drug Market Share by Application in 2019
Figure 86. Latin America Meningioma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Meningioma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Meningioma Drug Sales Market Share by Country in 2019
Figure 89. Latin America Meningioma Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Meningioma Drug Market Share by Type in 2019
Figure 97. Latin America Meningioma Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Meningioma Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Meningioma Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Meningioma Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Meningioma Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Meningioma Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Meningioma Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Meningioma Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Meningioma Drug Market Share by Application in 2019
Figure 110. North America Meningioma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Meningioma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Meningioma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Meningioma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Meningioma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Meningioma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Meningioma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Meningioma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Meningioma Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Meningioma Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…- 上衣腫治療薬の世界市場（～2026年） Market Analysis and Insights: Global Ependymoma Drug Market The global Ependymoma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ependymoma Drug Scope and Market Size Ependymoma Drug market is segmented by Type, …
- ポンチングリオーマ治療薬の世界市場（～2026年） Market Analysis and Insights: Global Pontine Glioma Drug Market The global Pontine Glioma Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pontine Glioma Drug Scope and Market Size Pontine Glioma Drug market is seg…
- 大麻薬の世界市場（～2026年） Drugs with chemicals taken directly from the marijuana plant，or with synthetic versions of chemicals naturally found in marijuana. Market Analysis and Insights: Global Cannabis Drug Market The global Cannabis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
- 乱用薬物検査サービスの世界市場（～2026年） Drug of Abuse Testing Services is the use of testing services to avoid the negative effects of drug abuse, to reduce the accidents. In addition to rise in number of substance abusers and increase in number of government initiatives to avoid ill effects of substance abuse at workplace & reduce number…